All Episodes

Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)

Reforms pending at USPSTF, plus, FDA rejects promising melanoma drug for the second time

On the joys of reporting on art as a tool for cancer education